Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Express Scripts
Medtronic
Baxter
Mallinckrodt

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,741,338

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,741,338 protect, and when does it expire?

Patent 7,741,338 protects AFINITOR and is included in one NDA.

This patent has seventy patent family members in thirty-seven countries.

Summary for Patent: 7,741,338
Title:Macrolides
Abstract: The invention relates to the stabilization of poly-ene macrolides and to a particular macrolide obtained in crystalline form.
Inventor(s): Navarro; Francois (Bruebach, FR), Petit; Samuel (Mont Saint-Aignan, FR), Stone; Guy (Crosshaven, IE)
Assignee: Novartis AG (Basel, CH)
Application Number:12/497,728
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,741,338
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,741,338

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,741,338

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9826882.4Dec 7, 1998
United Kingdom9904934.8Mar 4, 1999

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
Moodys
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.